U.S. P2Y12 Inhibitors Market Analysis & Forecast 2032

P2Y12 is a chemoreceptor for adenosine diphosphate (ADP) that belongs to the Gi class of a group of G protein-coupled (GPCR) purinergic receptors. The P2Y12 receptor is involved in platelet aggregation and is thus a biological target for the treatment of thromboembolisms and other clotting disorders. P2Y12 receptor blocker group of drugs includes clopidogrel, ticlopidine, ticagrelor, prasugrel, cangrelor, and others.

The U.S. P2Y12 inhibitors market is estimated to have around US$ 215.7 Mn in 2021, and is expected to exhibit a CAGR of 3.8% during the forecast period (2021-2028).

Figure 1. U.S. P2Y12 Inhibitors Market Share (%) in Terms of Value, By Drug, 2021

To learn more about this report, Request sample copy

The rising incidence of cardiovascular diseases is expected to drive the market growth during the forecast period.

The rising incidence of cardiovascular diseases in the U.S. is expected to drive the growth of the U.S. P2Y12 Inhibitors market over the forecast period. For instance, according to the data published in Centers for Disease Control and Prevention in September 2021, it is estimated that heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the U.S. Moreover, about 659,000 people in the U.S die from heart disease each year.

Figure 2. U.S. P2Y12 Inhibitors Market Share (%), By Distribution Channel, 2021

To learn more about this report, Request sample copy

Increasing product approvals is expected to drive the market growth during the forecast period.

Key players operating in the market are focusing on product approvals which is expected to drive the market growth over forecast period. For instance, in June 2020, AstraZeneca, a biopharmaceutical company’s, Brilinta (ticagrelor) had been approved in the U.S. to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of heart disease.

U.S. P2Y12 Inhibitors Market– Impact of Coronavirus (COVID-19) Pandemic

The coronavirus (COVID-19) pandemic and lockdown in various countries across the globe has impacted the financial status of businesses in all sectors. Private healthcare sector is one of the sectors, which is majorly impacted by the COVID-19 pandemic. Moreover, coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the severe oral mucositis medications businesses of various companies, across the regions such as North America, as COVID 19 pandemic has led to unprecedented lockdown in several countries such as the U.S. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products. Thus, COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) by its financial impact on firms and financial markets. Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments in the past few months, while countries such as Brazil, France, Russia, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of drug products. Due to severe shortage of medical resources at the front line, only patients diagnosed with serious conditions can be hospitalized. Unfortunately, the pathogenic mechanism of the virus has not been identified completely, though, there is presence of vaccines and drugs manufactured by the companies for prevention and treatment of COVID-19. The COVID-19 pandemic has impacted the global economy and in turn, the U.S. P2Y12 inhibitors market.

 U.S. P2Y12 Inhibitors Market: Restraint

The major factors that may hinder growth of the U.S. P2Y12 inhibitors market include potential side effects of drugs. For instance, side effects of  P2Y12 inhibitors include diarrhea, itching, nausea, skin rash, and stomach pain. Moreover, ticlopidine may lead to a very low white blood cell count or an immune disorder that destroys platelets. Ticagrelor may cause episodes of shortness of breath.

Key Players

Major players operating in the U.S. P2Y12 inhibitors market include Mylan N.V., Bristol-Myers Squibb, Dr Reddy's Laboratories, Teva Pharmaceuticals USA, Inc., AstraZeneca, Genentech,  Eli Lilly and Company,  Panacea Biotec,  CHIESI USA, Inc., Lupin, Cipla, and Biocon.